Skip to main content
. 2022 May;11(5):694–709. doi: 10.21037/tau-22-312

Figure 2.

Figure 2

Survival time based on IMDC stratification. (A) The PFS of patients in the IMDC favorable-risk group was significantly better than that of patients in the IMDC intermediate-risk group; (B) the PFS was significantly longer in patients with 1 risk factor than in patients with 2 risk factors. IMDC, International Metastatic renal cell carcinoma Database Consortium; PFS, progression-free survival.